Loading data for CGTX — first visit, this takes a few seconds.

Alerta

Cognition Therapeutics In... (CGTX)

: CGTX · Precio en tiempo real · USD

n/a

n/a (n/a)

Al cierre: Invalid Date

El precio, las cifras principales y las últimas noticias, en un solo sitio.

No hay datos disponibles

Precio de compra	n/a
Capitalización de mercado	n/a
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-16.77M
	1.78
	n/a
	n/a
	-4.47
P/B (TTM)	2.84
P/S (TTM)	n/a
Fecha de resultados	Nov 12, 2025

Precio de venta	n/a
Volumen	NaN
Volumen medio (20D)	n/a
Abierto	n/a
Anterior Cerrar	n/a
Rango del día	n/a - n/a
Rango de 52 semanas	n/a - n/a
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de CGTX

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studi...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Oct 8, 2021

Empleados 14

Bolsa de Valores NasdaqCM

Símbolo bursátil CGTX

Sitio web https://www.cogrx.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Cognition Therapeutics fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -23.49M, una disminución de -30.86%.

Estados financieros

Sorpresa de resultados

Cognition Therapeutics ha publicado sus resultados trimestrales en Aug 6, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.
EPS de -0.04 supera las estimaciones en 0.02, con 63.64% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Cognition Therapeutics Inc. publique sus resultados el Nov 12, 2025, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

2 semanas hace · Zacks

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Cognition Therapeutics (CGTX) delivered earnings and revenue surprises of +33.33% and -120.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stoc...

2 meses hace · Stocktwits

Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33%

The company reported that the U.S. Food and Drug Administration aligned with the company on several key aspects of the Phase 3 study, which is expected to begin in mid-2027.

2 meses hace · InvestorsHub

Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX)

Cognition Therapeutics (NASDAQ:CGTX) shares gained 5% after the company announced that it had received written feedback from the U. S.

2 meses hace · Insider Monkey

Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies?

We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. Cognition Therapeutics, Inc. (NASDAQ:CGTX) is one of the most popular penny stocks on Robinhood. TheFly report...

3 meses hace · Exec Edge

Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs

By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the recent outbreak of the hantavirus on a cruise ship highlights the need for broad-spectrum antiviral drugs such as NV-387. The hantavirus gets i...

Página 1 de 2